摘要
目的 评价乙型病毒性肝炎肝硬化(HB+C)经由恩替卡韦联合水飞蓟宾药物治疗的安全有效性。方法 选取2021年1-2022年1月本院收治的60例HB+C患者为研究对象,据随机数表法将患者分组,即对照组(单予恩替卡韦,30例)与观察组(联合水飞蓟宾药物治疗,30例),对比两组临床疗效。结果 临床疗效、不良反应分析,观察组均优于对照组,差异有统计学意义(χ^(2)=5.192,4.320;P<0.05);观察组患者的症状改善时间(5.08±1.11)d及住院时间(9.11±0.85)d,对照组依次为(8.12±1.72)d、(12.09±2.03)d,差异显著(t=8.134,7.417;P=0.000)。且观察组治疗后肝功能指标即TBIL(27.32±3.54)μmol/L、PT(11.88±2.32)s、ALB(37.88±4.82)g/L、ALT(44.57±14.12)U/L,纤维化指标即HA(107.14±66.18)μg/L、Ⅳ-C(67.09±20.72)μg/L、PCⅢ(95.49±30.21)μg/L水平均优于对照组(P<0.05)。结论 恩替卡韦联合水飞蓟宾药物治疗可有效缓解HB+C患者疾病症状,缩短其症状改善及住院时间,整体疗效显著,在肝功能改善的同时,可调节肝纤维化指标,临床预后良好,此方案值得推广。
Objective To evaluate safety and effect of entecavir combined with silybin in treatment of hepatitis B cirrhosis(HB+C).Methods The paper chose 60 HB+C patients admitted to our hospital from January 2021 to January 2022 as study objects,and divided them into control group(30 cases,treated with entecavir monotherapy)and observation group(30 cases,with silybin in combination)with random number table method.Clinical effect between two groups was compared.Results Clinical effect and adverse reaction of observation group was better than control group,with statistically significant difference(χ^(2)=5.192,4.320;P<0.05).Symptom improvement time of observation group was(5.08±1.11)days and length of stay was(9.11±0.85)days,while that of control group was(8.12±1.72)days and(12.09±2.03)days respectively,with significant difference(t=8.134,7.417;P=0.000).Liver function index of observation group after treatment was T BIL(27.32±3.54)μMol/L,PT(11.88±2.32)s,ALB(37.88±4.82)g/L,ALT(44.57±14.12)U/L,fibrosis index was HA(107.14±66.18)μg/L、Ⅳ-C(67.09±20.72)μg/L、PCⅢ(95.49±30.21)μg/L,better than control group(P<0.05).Conclusion Combination of entecavir and silybin can alleviate symptoms of HB+C patients effectively,shorten symptom improvement and length of stay,with significant overall curative effect.While improving liver function,it can regulate liver fibrosis indicators and achieve good clinical prognosis,which is worthy of promotion.
作者
魏丹
WEI Dan(Baicheng Central Hospital,Baicheng,Jilin 137000)
出处
《智慧健康》
2023年第13期195-198,共4页
Smart Healthcare
